Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

A recent study published in JAMA Psychiatry has uncovered promising evidence suggesting that glucagon-like peptide-1 (GLP-1) ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of liraglutide from the 503B Bulks List, a registry of substances that ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

An observational analysis finds the drugs may lower the risk of substance abuse and cognitive issues. But the findings need ...

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

GLP-1 agonists for weight loss are now commonly used for adults, but might they also be an effective treatment for younger ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

(HealthDay News) — The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 (GLP-1) receptor agonist ...